ArticleJournal of clinical & cellular immunology2011
Th2 Cytokines and Atopic Dermatitis.
Article in Journal of clinical & cellular immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 311 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
311 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Impact of Probiotics on Atopic Dermatitis in Pediatric Patients: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Association between atopic dermatitis and risk of stroke: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Association Between Atopic Dermatitis and Suicidality: A Systematic Review and Meta-analysis.JAMA dermatology · 2019Pooled it
- Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate-to-Severe Atopic Dermatitis.Allergy · 2026Trial
- Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials.Clinical and translational science · 2024Trial
- The randomized, single- and multiple- ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects.Clinical and translational science · 2023Trial
- Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis.Acta dermato-venereologica · 2022Trial
- The Antimicrobial Activity ofMolecules (Basel, Switzerland) · 2021Trial
- IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.The Journal of investigative dermatology · 2020Trial
- Aqueous extract ofPharmaceutical biology · 2026Article
- Atopic dermatitis management: integrating disease mechanisms with precision medicine and nanotechnology-based targeted therapies.Irish journal of medical science · 2026Review
- Ameliorative effects ofThe journal of allergy and clinical immunology. Global · 2026Article
- Rewiring Atopic Dermatitis: Alarmin Cytokines at the Core of Barrier-Immune-Neuro-Microbiome Networks.Clinical reviews in allergy & immunology · 2026Review
- In Utero Per- and Polyfluoroalkyl Substances (PFAS) Exposure and Changes in Infant T Helper Cell Development among UPSIDE-ECHO Cohort Participants.Environmental health perspectives · 2026Article
- Associations of Comorbid Atopic Dermatitis, Food Allergy, and Respiratory Allergic Diseases with Somatic Problems in Children: A Birth Cohort Study.Children (Basel, Switzerland) · 2026Article
- An AI-augmented review of childhood atopic dermatitis biomarkers across genetic, immune, microbial, and metabolic domains.Molecular medicine (Cambridge, Mass.) · 2026Review
- The Inflammatory Response in the Murine Ovalbumin-Induced Skin Inflammation Model Is Robust Despite Major Gut Microbiota Differences.Clinical and translational science · 2026Article
- The Role of and Therapeutic Strategies for Eosinophils in Atopic Dermatitis.Biomedicines · 2026Review
- Crystal structure and molecular dynamics simulations of rademikibart Fab-IL-4Rα complex reveal biochemical basis for next-generation potent IL-4Rα inhibition in type 2 allergic and inflammatory diseases.bioRxiv : the preprint server for biology · 2026Article
- A λ-Carrageenan-Enriched Sulfated Galactan fromMarine drugs · 2026Article
251 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Atopic dermatitis (AD), a chronic relapsing inflammatory skin disease, is increasing in prevalence around the world. Intensive research is ongoing to understand the mechanisms involved in the development of AD and offer new treatment options for patients suffering from AD. In this review, we highlight the importance of allergic Th2 responses in the development of the disease and summarize relevant literature, including genetic studies, studies of human skin and mechanistic studies on keratinocytes and mouse models of AD. We discuss the importance of the skin barrier and review recent findings on the pro-Th2 cytokines TSLP, IL-25, and IL-33, notably their ability to polarize dendritic cells and promote Th2 responses. After a brief update on the contribution of different T-cell subsets to AD, we focus on Th2 cells and the respective contributions of each of the Th2 cytokines (IL-4, IL-13, IL-5, IL-31, and IL-10) to AD. We conclude with a brief discussion of the current gaps in our knowledge and technical limitations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.